title: Dose-dependent effect of aspirin on the level of sphingolipids in human blood.
abstract: OBJECTIVE
  Aspirin is an antiplatelet drug which is commonly used in secondary prevention in ischemic heart disease and cerebrovascular events, and in newly diagnosed myocardial infarction. The aim of the present study was to examine effect of aspirin on the level of selected sphingolipid intermediates in plasma, erythrocytes and platelets.
  
  
  METHODS
  Forty two healthy volunteers participated in the study. They were divided into two groups. In one group aspirin was given orally, daily, for one week in a dose of 75 mg (n=25). The subjects from the second group received one 300 mg dose of the drug (n=17). In both groups the blood was taken 4h after the last dose of aspirin. The following sphingolipid intermediates were quantified using high-pressure liquid chromatography: sphinganine, sphingosine, sphingosine-1-phosphate (S1P), sphinganine-1-phosphate (SA1P) and ceramide.
  
  
  RESULTS
  It was found that lower dose of aspirin increased the level of S1P and ceramide in erythrocytes (by 23 and 37%, respectively) having no effect on plasma and platelet sphingolipid levels. Higher dose of the drug reduced S1P and SA1P concentration in the plasma (by 16 and 10%, respectively).
  
  
  CONCLUSIONS
  We conclude that aspirin interferes with sphingolipid metabolism in blood and that this effect depends on a dose of the drug. Since S1P is a potent cardioprotectant, the reduction in its plasma concentration after the loading dose of aspirin could be undesired side effect of the drug.
authors.forename: M
authors.initials: M
authors.lastname: Knapp
authors.forename: A
authors.initials: A
authors.lastname: Lisowska
authors.forename: P
authors.initials: P
authors.lastname: Knapp
authors.forename: M
authors.initials: M
authors.lastname: Baranowski
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D001241:Aspirin / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002518:Ceramides / Q000097:blood / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D005260:Female; D064368:Healthy Volunteers; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008246:Lysophospholipids / Q000097:blood / Q000378:metabolism; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000097:blood / Q000494:pharmacology; D010976:Platelet Count; D013107:Sphingolipids / Q000097:blood* / Q000378:metabolism; D013110:Sphingosine / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002518:Ceramides; D006454:Hemoglobins; D008246:Lysophospholipids; D010975:Platelet Aggregation Inhibitors; D013107:Sphingolipids; C060506:sphingosine 1-phosphate; D013110:Sphingosine; C005682:safingol; D001241:Aspirin